Second-line therapies in hepatocellular carcinoma: Emergence of resistance to sorafenib

Augusto Villanueva; Josep M. Llovet

doi:10.1158/1078-0432.CCR-12-0151

Second-line therapies in hepatocellular carcinoma: Emergence of resistance to sorafenib

Augusto Villanueva, Josep M. Llovet

Research output: Contribution to journal › Article › peer-review

90 Scopus citations

Abstract

Second-line therapies are needed for patients with advanced hepatocellular carcinoma who progress after sorafenib. Positive signals seen with brivanib in phase II studies, reported herein, have yet to be confirmed in phase III trials. Identification of the molecular mechanisms driving sorafenib resistance should guide drug development strategies in this setting.

Original language	English
Pages (from-to)	1824-1826
Number of pages	3
Journal	Clinical Cancer Research
Volume	18
Issue number	7
DOIs	https://doi.org/10.1158/1078-0432.CCR-12-0151
State	Published - 1 Apr 2012

Access to Document

10.1158/1078-0432.CCR-12-0151

Cite this

@article{691d259041a34639bcbba44e175cab82,

title = "Second-line therapies in hepatocellular carcinoma: Emergence of resistance to sorafenib",

abstract = "Second-line therapies are needed for patients with advanced hepatocellular carcinoma who progress after sorafenib. Positive signals seen with brivanib in phase II studies, reported herein, have yet to be confirmed in phase III trials. Identification of the molecular mechanisms driving sorafenib resistance should guide drug development strategies in this setting.",

author = "Augusto Villanueva and Llovet, {Josep M.}",

year = "2012",

month = apr,

day = "1",

doi = "10.1158/1078-0432.CCR-12-0151",

language = "English",

volume = "18",

pages = "1824--1826",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "7",

}

TY - JOUR

T1 - Second-line therapies in hepatocellular carcinoma

T2 - Emergence of resistance to sorafenib

AU - Villanueva, Augusto

AU - Llovet, Josep M.

PY - 2012/4/1

Y1 - 2012/4/1

N2 - Second-line therapies are needed for patients with advanced hepatocellular carcinoma who progress after sorafenib. Positive signals seen with brivanib in phase II studies, reported herein, have yet to be confirmed in phase III trials. Identification of the molecular mechanisms driving sorafenib resistance should guide drug development strategies in this setting.

AB - Second-line therapies are needed for patients with advanced hepatocellular carcinoma who progress after sorafenib. Positive signals seen with brivanib in phase II studies, reported herein, have yet to be confirmed in phase III trials. Identification of the molecular mechanisms driving sorafenib resistance should guide drug development strategies in this setting.

UR - http://www.scopus.com/inward/record.url?scp=84859383549&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-12-0151

DO - 10.1158/1078-0432.CCR-12-0151

M3 - Article

C2 - 22355010

AN - SCOPUS:84859383549

SN - 1078-0432

VL - 18

SP - 1824

EP - 1826

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 7

ER -

Second-line therapies in hepatocellular carcinoma: Emergence of resistance to sorafenib

Abstract

Access to Document

Fingerprint

Cite this